TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

About this trial

The primary objective of this study is to assess the feasibility of treatment with bintrafusp alfa combined with definitive chemoradiation (carboplatin, paclitaxel and radiation) in patients with squamous cell carcinoma of the esophagus or gastroesophageal junction.

Eligibility criteria

Qualifiers

Histologically proven squamous cell carcinoma of the esophagus or gastro esophageal junction.

Surgically irresectable (T1-T4a, N0 or N+, M0), as determined by Endoscopic Ultra Sound (EUS), PET scan and diagnostic CT scan of neck, thorax and abdomen. Patients with M1 disease solely on the basis of supraclavicular metastasis are eligible. Patients with resectable tumors refusing radical surgery are eligible.

Locoregional recurrences without distant metastasis after surgery alone or endoscopical resection

Locoregional recurrences without distant metastasis after neoadjuvant chemoradiation + resection or definitive chemoradiation outside the previously irradiated area, provided that full dose of radiation can safely be delivered.

Disqualifiers

Past or current history of malignancy other than entry diagnosis interfering with prognosis of esophageal cancer.

Patient with tracheo-esophageal fistula or extension into the mucosal layer of the trachea, highly at risk to develop fistula. Thus, tumor extension to the trachea is allowed, but not through the trachea.

Patients with pathological lymph nodes at both supraclavicular and truncus coeliacus level.

Pregnancy (positive serum pregnancy test), planning to become pregnant, and lactation.

Trial design

Treatments tested in this trial

  • External beam radiotherapy
  • Bintrafusp alfa
  • Paclitaxel
  • Carboplatin

Treatment groups

49 Participants
are divided into 1 treatment group

Sponsors and collaborators

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Lead sponsor

UMC Utrecht

Collaborator

Catharina Ziekenhuis Eindhoven

Collaborator

Institute Verbeeten

Collaborator

Elisabeth-TweeSteden Ziekenhuis

Collaborator

Leiden University Medical Center

Collaborator

Radiotherapeutic Institute Friesland

Collaborator

Frisius Medisch Centrum

Collaborator

Radiotherapy Group Deventer

Collaborator

Deventer Ziekenhuis

Collaborator

Rijnstate Hospital

Collaborator

Erasmus Medical Center

Collaborator

The Netherlands Cancer Institute

Collaborator

Isala

Collaborator

University Medical Center Groningen

Collaborator

Ziekenhuisgroep Twente

Collaborator